Shenzhen Bioeasy Biotechnology Co. Ltd.
Shenzhen Bioeasy Biotechnology Co., Ltd., together with its subsidiaries, provides rapid food testing reagents and instruments in China and internationally. The company offers test kits, including veterinary, melamine, mycotoxin, pesticide, adulteration, ATP, vitamin, and others; equipment, such as incubator, reader, suitcase lab, automatic pressers, and others; and materials comprising pretreatm… Read more
Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) - Total Liabilities
Latest total liabilities as of September 2025: CN¥571.21 Million CNY
Based on the latest financial reports, Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) has total liabilities worth CN¥571.21 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shenzhen Bioeasy Biotechnology Co. Ltd. - Total Liabilities Trend (2016–2024)
This chart illustrates how Shenzhen Bioeasy Biotechnology Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shenzhen Bioeasy Biotechnology Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Shenzhen Bioeasy Biotechnology Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hangzhou Minsheng Healthcare Co Ltd
SHE:301507
|
China | CN¥289.53 Million |
|
APAQ Technology Co Ltd
TW:6449
|
Taiwan | NT$3.49 Billion |
|
YeaShin International Development Co Ltd
TWO:5213
|
Taiwan | NT$53.02 Billion |
|
Sodick Co., Ltd.
PINK:SDCKF
|
USA | $54.29 Billion |
|
Exmar NV
PINK:EXMRF
|
USA | $366.84 Million |
|
Vigil Neuroscience Inc
NASDAQ:VIGL
|
USA | $45.44 Million |
|
Oxford Biomedica plc
PINK:OXBDF
|
USA | $183.59 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Shenzhen Bioeasy Biotechnology Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.63 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenzhen Bioeasy Biotechnology Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenzhen Bioeasy Biotechnology Co. Ltd. (2016–2024)
The table below shows the annual total liabilities of Shenzhen Bioeasy Biotechnology Co. Ltd. from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥586.92 Million | +15.62% |
| 2023-12-31 | CN¥507.61 Million | +59.75% |
| 2022-12-31 | CN¥317.75 Million | +54.29% |
| 2021-12-31 | CN¥205.94 Million | +98.20% |
| 2020-12-31 | CN¥103.90 Million | +13.75% |
| 2019-12-31 | CN¥91.35 Million | +23.08% |
| 2018-12-31 | CN¥74.22 Million | +25.38% |
| 2017-12-31 | CN¥59.19 Million | -12.73% |
| 2016-12-31 | CN¥67.83 Million | -- |